Quick Answer
Olema Pharmaceuticals, Inc. reported Operating Income of -$178.70 million for fiscal year 2025.
Olema Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$178.70M | -25.6% |
| 2024 | -$142.26M | -35.5% |
| 2023 | -$104.96M | +1.9% |
| 2022 | -$106.99M | -49.7% |
| 2021 | -$71.49M | -232.1% |
| 2020 | -$21.53M | -398.0% |
| 2019 | -$4.32M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$45.88M | -21.9% | +4.2% |
| June 30, 2025 | -$47.86M | -42.7% | -37.3% |
| March 31, 2025 | -$34.87M | -1.6% | +7.3% |
| September 30, 2024 | -$37.62M | -61.2% | -12.2% |
| June 30, 2024 | -$33.53M | -55.2% | +2.4% |
| March 31, 2024 | -$34.34M | -16.0% | -47.1% |
| September 30, 2023 | -$23.34M | -0.5% | -8.1% |
| June 30, 2023 | -$21.60M | +35.1% | +27.0% |
- Olema Pharmaceuticals, Inc. showed a decrease of -25.6% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Olema Pharmaceuticals, Inc.’s operating income has declined by 4033.7% (from -$4.32 million to -$178.70 million).
- The most recent figure is from Olema Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: